Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.7152W HIGH $16.00
Volume
267.28 K
Value Traded
722.26 K
Short % Float
8.8%
-5.73%Week
-16.97%1 Month
-47.99%3 Month
-82.17%6 Month
-93.83%5 Year
-94.35%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
47.57 M
EPS (TTM)
-1.44
P/E Ratio
-
Ent. Value
33.63 M
Total Shares
26.28 M
Float Shares
18.94 M
Insiders
27.95%
Institutions
15.83%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
ELTX Catalyst Timeline
Dated clinical, regulatory and corporate events for Elicio Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Elicio Therapeutics, Inc.
271Total events
14Upcoming
56Tier-1 (high impact)
2020 to 2027Coverage
Upcoming catalysts 2
Event history 50
▼Primary Endpoint MissedELI-002 7PClinical Data
Phase 2 AMPLIFY-7P trial did not meet primary endpoint
adjuvant pancreatic ductal adenocarcinomasource ↗
▲Trial InitiationELI-002 7PTrial
MSK-led Phase 1 neoadjuvant trial activated
neoadjuvant pancreatic cancersource ↗
▼Topline ReadoutELI-002 7PClinical Data
Phase 2 AMPLIFY-7P trial did not meet primary endpoint
adjuvant pancreatic cancersource ↗
▲Trial InitiationELI-002 7PTrial
Activation of investigator-initiated Phase 1 neoadjuvant study of ELI-002 7P
pancreatic ductal adenocarcinomasource ↗
▲Quarterly UpdateCorporate
Elicio Therapeutics added to Russell 2000 and Russell 3000 indexes
◆Oral PresentationELI-002 7PPresentation
Virtual KOL event to discuss complete response observations
metastatic mKRAS pancreatic cancersource ↗
▲Full ResultsELI-002 7PClinical Data
Complete responses observed in three patients after ELI-002 7P and subsequent nivolumab-based therapy
metastatic mKRAS pancreatic cancersource ↗
▼Primary Endpoint MissedELI-002 7PClinical Data
AMPLIFY-7P did not meet pre-specified primary endpoint of DFS in ITT population
adjuvant mKRAS-driven pancreatic ductal adenocarcinomasource ↗
◆Full ResultsELI-002 7PClinical Data
Full results from AMPLIFY-7P reported, including post-hoc analyses
adjuvant mKRAS-driven pancreatic ductal adenocarcinomasource ↗
▲Subgroup AnalysisELI-002 7PClinical Data
Post-hoc analysis in R0 resected patients showed DFS HR 0.65, p=0.048
adjuvant mKRAS-driven pancreatic ductal adenocarcinomasource ↗
▲Biomarker DataELI-002 7PClinical Data
mKRAS-specific T cell responses strongly correlated with improved DFS (HR 0.22, p<0.0001)
adjuvant mKRAS-driven pancreatic ductal adenocarcinomasource ↗
◆Topline ReadoutELI-002 7PClinical Data
Event-driven primary DFS analysis of ELI-002 7P in AMPLIFY-7P
pancreatic ductal adenocarcinoma (PDAC)source ↗
▲Runway Guidance UpdateCorporate
Cash runway expected through Q2 2026, beyond anticipated DFS analysis
◆Timing GuidanceELI-002 7PPresentation
Event-driven primary disease-free survival analysis anticipated in 1H 2026
mKRAS-positive pancreatic cancersource ↗
◆Topline ReadoutELI-002 7PClinical Data
Event-driven primary DFS endpoint analysis anticipated in 1H 2026
pancreatic ductal adenocarcinomasource ↗
▲Runway Guidance UpdateCorporate
Cash runway expected into Q1 2026, beyond anticipated Phase 2 final analysis
●Trial InitiationELI-002 7PTrial
Planned investigator-initiated Phase 1 neoadjuvant trial of ELI-002 7P combined with mFOLFIRINOX with or without anti-PD-1 antibody
resectable and borderline resectable pancreatic ductal adenocarcinomasource ↗
▲Biomarker DataELI-002 7PClinical Data
Antigen spreading to non-mKRAS neoantigens observed in 87% of evaluated patients in Phase 2 AMPLIFY-7P trial
mKRAS-positive pancreatic cancersource ↗
●Poster PresentationELI-004Presentation
Poster presentation of preclinical data for ELI-004
advanced solid tumorssource ↗
◆Late-BreakerELI-002Presentation
Late-breaking abstract poster presentation of clinical immunogenicity results from AMPLIFY-7P trial of ELI-002
mKRAS-driven pancreatic cancersource ↗
▲Oral PresentationELI-002 7PPresentation
AMPLIFY-7P Phase 2: T cell responses induced by ELI-002 7P at SITC 2025
mKRAS pancreatic ductal adenocarcinomasource ↗
▲Oral PresentationELI-004Presentation
Amphiphile (AMP)-Immunomodulator therapy controls growth and eradicates syngeneic solid tumors at SITC 2025
solid tumorssource ↗
▲Enrollment UpdateELI-002 7PTrial
Fewer disease progressions and deaths than projected observed as of November 6, 2025
pancreatic ductal adenocarcinomasource ↗
▲Oral PresentationELI-002 7PPresentation
Updated Phase 2 AMPLIFY-7P data presented at SITC Annual Meeting
pancreatic ductal adenocarcinomasource ↗
▲Additional DataELI-002 7PClinical Data
Preliminary analysis shows mKRAS-specific T-cell responses across diverse HLA backgrounds in AMPLIFY-7P trial
mKRAS-driven pancreatic cancersource ↗
◆Timing GuidanceELI-002Presentation
Event-driven final DFS analysis anticipated in Q4 2025
mKRAS-positive pancreatic cancersource ↗
◆Primary Endpoint MetELI-002 7PClinical Data
Final disease-free survival analysis anticipated
mKRAS-driven pancreatic cancersource ↗
◆Topline ReadoutELI-002 7PClinical Data
Final disease-free survival analysis anticipated
pancreatic ductal adenocarcinoma (PDAC)source ↗
▲Oral PresentationELI-002 7PPresentation
Robust T cell responses across diverse HLA backgrounds announced
pancreatic ductal adenocarcinomasource ↗
▲Full ResultsELI-002 7PClinical Data
Immunogenicity data showing 99% of evaluable patients generated strong mKRAS-specific T cell responses
mKRAS-driven pancreatic cancersource ↗
▲DSMB ReviewELI-002 7PTrial
IDMC recommended trial continue to final analysis without modifications
mKRAS-driven pancreatic cancersource ↗
▲PublicationELI-002Presentation
Publication of updated Phase 1 AMPLIFY-201 follow-up data in Nature Medicine
mKRAS-positive pancreatic and colorectal cancerssource ↗
▲DSMB ReviewELI-002Trial
IDMC recommends Phase 2 AMPLIFY-7P study continue without modification to final DFS analysis
mKRAS-positive pancreatic cancersource ↗
▲DSMB ReviewELI-002 7PTrial
IDMC positive recommendation to continue AMPLIFY-7P study to final analysis without modification
pancreatic cancersource ↗
▲DSMB ReviewELI-002 7PTrial
IDMC recommends continuation of AMPLIFY-7P trial without modifications
pancreatic ductal adenocarcinoma (PDAC)source ↗
Past FDA Catalysts and PDUFA Decisions
How ELTX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-06-30 | ELI-002 7P | Phase 2 data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D21 / 100
Pipeline Score
$1M
Pipeline Value
Richly Valued
Valuation Signal
2
Drugs Scored
0.0x
rNPV / MCap
Top 93%
Micro Cap(rank 612 of 658)
Percentile Rank
Elicio Therapeutics, Inc. faces pipeline headwinds (21/100), with $56M risk-adjusted pipeline value, led by ELI-002 7P in Pancreatic Ductal Adenocarcinoma (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ELI-002 7P Small moleculeNCT05726864 | Pancreatic Ductal Adenocarcinoma | Phase 1 | ACTIVE NOT_RECRUITING | 158 | Nov 1, 2026 |
Clinical Trial Results
Readouts, endpoints and source filings for every ELTX program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| DeMuth PeterOfficer (Chief Scientific Officer) | Grant/Award | 52,832 52,832 held | $0.00 | 07/16/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ELTX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Ikarian Capital, LLC | 0 % | 418.00 K | 107.10 K |
ELTX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ELTX ranks across every disease it competes in
Competitive Position is a premium feature
See how ELTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialELTX News
ELTXElicio Therapeutics Announces Late-Breaking Phase 2 AMPLIFY-7P Data Selected for Proffered Paper Oral Presentation at ESMO Congress 2026
Elicio Therapeutics announced that new analyses from the Phase 2 AMPLIFY-7P study of ELI-002 7P will be presented at the ESMO Congress 2026. These findings aim to deepen understanding of the drug's clinical potential in treating pancreatic cancer and inform a refined Phase 3 development strategy. Despite not meeting its primary endpoint, the study has provided valuable insights.
Read more →ELTXElicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment Conference
Elicio Therapeutics will participate in the H.C. Wainwright 28th Annual Global Investment Conference from September 14-16, 2026. CEO Robert Connelly and CSO Pete DeMuth will engage in a fireside chat on September 14 at 2:00 PM ET. The event will be accessible via a live webcast and replay for 90 days.
Read more →ELTXElicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference
Elicio Therapeutics will participate in one-on-one meetings at the Wells Fargo 21st Annual Healthcare Conference from September 8-10, 2026. The company focuses on developing next-generation immunotherapies for KRAS-driven cancers. Their lead program, ELI-002 7P, targets common KRAS mutations, aiming for effective cancer treatment. Elicio's approach emphasizes off-the-shelf solutions for rapid patient access.
Read more →ELTXElicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Elicio Therapeutics reported its Q2 2026 financial results, highlighting multiple complete responses in ongoing trials for ELI-002 7P. Despite the Phase 2 AMPLIFY-7P trial not meeting its primary endpoint, the company is refining its Phase 3 strategy. A new Phase 1 combination study is set to begin in Q4 2026, supported by recent financing.
Read more →ELTXElicio Therapeutics Announces Activation of the Investigator-Initiated Phase 1 Study of Neoadjuvant ELI-002 7P for Pancreatic Ductal Adenocarcinoma
Elicio Therapeutics has announced the activation of a Phase 1 study evaluating ELI-002 7P for pancreatic ductal adenocarcinoma (PDAC). Conducted by Memorial Sloan Kettering Cancer Center, the study aims to enroll 20 patients and assess the combination of ELI-002 7P with chemotherapy and an anti-PD1 checkpoint inhibitor. This trial seeks to generate insights into the treatment's effectiveness in improving patient outcomes.
Read more →ELTX▼ -15%on this news
Elicio Therapeutics Announces Closing of $15 Million Registered Direct Offering
Elicio Therapeutics has announced the successful closing of a $15 million registered direct offering. The funds will primarily be used to support the Phase 1 clinical development of ELI-002 for metastatic pancreatic cancer, as well as for general corporate purposes. The offering was led by new institutional investors and included participation from an existing shareholder.
Read more →ELTX▼ -37.4%on this newsshared move
Elicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering
Elicio Therapeutics announced a registered direct offering, raising approximately $15 million through the sale of 4,380,313 shares. The funds will primarily be used to support the Phase 1 clinical development of ELI-002 for metastatic pancreatic cancer and for general corporate purposes. The offering is expected to close around July 6, 2026.
Read more →ELTXElicio Therapeutics Added to Russell 2000® and Russell 3000® Indexes
Elicio Therapeutics has been added to the Russell 2000 and Russell 3000 indexes, effective June 26, 2026. This milestone indicates increased recognition of the company's advancements in immunotherapy for KRAS-driven cancers. CEO Robert Connelly emphasized that this inclusion enhances visibility among institutional investors and reflects the company's commitment to patient and shareholder value.
Read more →ELTX▲ +70.7%on this news
Elicio Therapeutics Reports Multiple Complete Responses After ELI-002 7P Treatment and Subsequent Therapy with Checkpoint Inhibition in Metastatic mKRAS Pancreatic Cancer
Elicio Therapeutics reported promising results from its Phase 2 AMPLIFY-7P study, where three patients with metastatic mKRAS pancreatic cancer achieved complete responses after receiving ELI-002 7P followed by nivolumab therapy. These findings suggest that ELI-002 7P may enhance the effectiveness of checkpoint inhibitors, leading to plans for a Phase 1 study to further investigate this combination. The company aims to refine its development strategy based on these observations.
Read more →ELTX▼ -72.5%on this newsshared move
Elicio Therapeutics Reports Results from Phase 2 AMPLIFY-7P Study and Outlines Refined Phase 3 Development Strategy for ELI-002 7P in Adjuvant Pancreatic Cancer
Elicio Therapeutics reported mixed results from its Phase 2 AMPLIFY-7P study of ELI-002 7P in adjuvant pancreatic cancer. While the study did not meet its primary endpoint of disease-free survival (DFS) in the intent-to-treat population, post-hoc analyses indicated significant DFS improvement in patients with lower residual disease. The company plans to refine its Phase 3 development strategy focusing on this subgroup, supported by promising immune response data.
Read more →ELTX▲ +5.9%on this news· ran to +22% by day 3
Elicio Therapeutics Announces Publication in Peer-Reviewed Journal Science Advances Highlighting Potent and Durable Immune Responses Driven by Company’s AMP-DNA Adjuvant Technology
Elicio Therapeutics announced the publication of a peer-reviewed manuscript in Science Advances detailing its AMP-DNA adjuvant technology. The research highlights robust immune responses initiated through targeted delivery to lymph nodes, showcasing improved efficacy over existing adjuvants. Notable findings include potent T cell activation and durable immune memory observed for at least nine months in preclinical models, including non-human primates. These developments signify a meaningful advancement in Elicio's immunotherapy pipeline aimed at treating various cancers.
Read more →ELTX▲ +17.2%on this news
Elicio Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Elicio Therapeutics reported its Q1 2026 financial results, highlighting significant fundraising efforts totaling $13 million. The company is focused on its Phase 2 AMPLIFY-7P trial for ELI-002 7P in pancreatic cancer, with a primary disease-free survival analysis expected mid-2026. Despite a slight increase in net loss, Elicio's cash runway is projected to support operations through Q4 2026.
Read more →ELTXElicio Therapeutics to Present at the Bank of America Healthcare Conference
Elicio Therapeutics will present at the Bank of America Healthcare Conference from May 12-14, 2026. Key executives, including CEO Robert Connelly, will discuss the company's innovative immunotherapy pipeline. Elicio's lead program, ELI-002, targets mKRAS-positive cancers and has shown promising clinical results. The presentation will be available via webcast for 90 days.
Read more →ELTX▲ +7%on this news
Elicio Therapeutics Reports Inducement Grants
Elicio Therapeutics announced the granting of 21,210 inducement stock options to a new employee as part of its hiring strategy. The options, approved by the Compensation Committee, allow the purchase of shares at $11.78 each and vest over four years. Elicio is focused on developing novel immunotherapies for high-prevalence cancers, leveraging its Amphiphile technology.
Read more →ELTX▲ +11.9%on this newsshared move
Elicio Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates
Elicio Therapeutics reported its financial results for 2025, highlighting progress in the Phase 2 AMPLIFY-7P trial for ELI-002 7P targeting KRAS-mutant pancreatic cancer. The company noted fewer disease progressions than projected and plans to expand ELI-002 7P's development. Despite a net loss of $39.5 million, Elicio's cash reserves are expected to sustain operations into Q3 2026.
Read more →ELTX▲ +10.4%on this news· ran to +39% by day 3
Elicio Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
Elicio Therapeutics will present at the TD Cowen 46th Annual Health Care Conference on March 4, 2026. CEO Robert Connelly and CSO Pete DeMuth will discuss the company's advancements in immunotherapy for cancer treatment. Elicio focuses on off-the-shelf therapies targeting mKRAS-positive cancers, with promising clinical trial data.
Read more →ELTXElicio Therapeutics Reports Inducement Grants - January 16, 2026
Elicio Therapeutics announced the grant of 22,400 inducement stock options to two new employees as part of their hiring process. The stock options were granted at a price of $7.81 per share and will vest over four years. Elicio is focused on developing innovative immunotherapies for high-prevalence cancers, including mKRAS-positive pancreatic and colorectal cancers, with promising clinical trial results.
Read more →About Elicio Therapeutics, Inc.
Headquarters451 D STREET, 5TH FLOOR, BOSTON, MA, 02210
BIOPHARMAWATCH ELITE PLUS
Trade the next ELTX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime